CN114222761A - 一种抗cld18a2的单域抗体 - Google Patents

一种抗cld18a2的单域抗体 Download PDF

Info

Publication number
CN114222761A
CN114222761A CN202080041701.3A CN202080041701A CN114222761A CN 114222761 A CN114222761 A CN 114222761A CN 202080041701 A CN202080041701 A CN 202080041701A CN 114222761 A CN114222761 A CN 114222761A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
sequence shown
cld18a2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080041701.3A
Other languages
English (en)
Other versions
CN114222761B (zh
Inventor
黄岩山
姚高峰
董佳里
温晓芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Doer Biologics Co Ltd
Original Assignee
Zhejiang Doer Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Doer Biologics Co Ltd filed Critical Zhejiang Doer Biologics Co Ltd
Publication of CN114222761A publication Critical patent/CN114222761A/zh
Application granted granted Critical
Publication of CN114222761B publication Critical patent/CN114222761B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/51—Stomach

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

一种抗CLD18A2的单域抗体。所述抗CLD18A2的单域抗体的互补决定区包括氨基酸序列如SEQ ID NO.4～11其中之一所示的CDR‑H1、氨基酸序列如SEQ ID NO.19～26其中之一所示的CDR‑H2、和氨基酸序列如SEQ ID NO.33～39其中之一所示的CDR‑H3。所述抗CLD18A2的单域抗体对于Claudin18.2具有良好的亲和力，且可以用于进一步构建双特异性抗体、抗体‑药物复合物、嵌合抗原受体等，且构建获得的双特异性抗体、抗体‑药物复合物、CAR‑T细胞等对于靶标细胞具有良好的靶向性和杀伤效果。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202080041701.3A 2020-07-14 2020-07-14 一种抗cld18a2的单域抗体 Active CN114222761B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/101789 WO2022011531A1 (zh) 2020-07-14 2020-07-14 一种抗cld18a2的单域抗体

Publications (2)

Publication Number Publication Date
CN114222761A true CN114222761A (zh) 2022-03-22
CN114222761B CN114222761B (zh) 2024-02-20

Family

ID=79554401

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080041701.3A Active CN114222761B (zh) 2020-07-14 2020-07-14 一种抗cld18a2的单域抗体

Country Status (2)

Country Link
CN (1) CN114222761B (zh)
WO (1) WO2022011531A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117551199A (zh) * 2023-11-16 2024-02-13 杭州荣谷生物科技有限公司 一种Claudin18.2纳米抗体的制备方法及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023134742A1 (zh) * 2022-01-14 2023-07-20 浙江道尔生物科技有限公司 一种三靶点抗肿瘤药物、其制备方法及其应用

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948693A1 (en) * 2005-11-24 2008-07-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CN101687929A (zh) * 2007-05-29 2010-03-31 加尼梅德药物公司 用于治疗癌症的抗密蛋白-18的单克隆抗体
US20130251711A1 (en) * 2010-11-22 2013-09-26 Innate Pharma Sa Nk cell modulating treatments and methods for treatment of hematological malignancies
US20150147763A1 (en) * 2012-05-09 2015-05-28 Ganymed Pharmaceuticals Ag Antibodies Against Claudin 18.2 Useful in Cancer Diagnosis
CN105315375A (zh) * 2014-07-17 2016-02-10 科济生物医药（上海）有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
EP3099706A1 (en) * 2014-01-29 2016-12-07 BioNTech AG Peptide mimotopes of claudin 18.2 and uses thereof
CN109311999A (zh) * 2015-08-11 2019-02-05 南京传奇生物科技有限公司 基于单结构域抗体的嵌合抗原受体及其使用方法
CN109762067A (zh) * 2019-01-17 2019-05-17 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN109790222A (zh) * 2016-07-08 2019-05-21 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用
CN110606891A (zh) * 2018-06-17 2019-12-24 上海健信生物医药科技有限公司 一种针对人cldn18.2的新型抗体分子, 抗原结合片段及其医药用途
CN110857322A (zh) * 2018-08-22 2020-03-03 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
CN110862454A (zh) * 2018-08-27 2020-03-06 南京圣和药业股份有限公司 一种抗Claudin18_2抗体及其应用
CN111235113A (zh) * 2020-01-21 2020-06-05 南京北恒生物科技有限公司 包含嵌合抗原受体的免疫细胞及其用途
CN111434692A (zh) * 2019-01-15 2020-07-21 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
US20210214433A1 (en) * 2018-07-25 2021-07-15 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
US20210230272A1 (en) * 2018-06-17 2021-07-29 L&L Biopharma Co., Ltd. Antibody targeting cldn18.2, bispecific antibody, adc, and car, and applications thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1948693A1 (en) * 2005-11-24 2008-07-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
CN101687929A (zh) * 2007-05-29 2010-03-31 加尼梅德药物公司 用于治疗癌症的抗密蛋白-18的单克隆抗体
US20130251711A1 (en) * 2010-11-22 2013-09-26 Innate Pharma Sa Nk cell modulating treatments and methods for treatment of hematological malignancies
US20150147763A1 (en) * 2012-05-09 2015-05-28 Ganymed Pharmaceuticals Ag Antibodies Against Claudin 18.2 Useful in Cancer Diagnosis
EP3099706A1 (en) * 2014-01-29 2016-12-07 BioNTech AG Peptide mimotopes of claudin 18.2 and uses thereof
CN105315375A (zh) * 2014-07-17 2016-02-10 科济生物医药（上海）有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
CN109311999A (zh) * 2015-08-11 2019-02-05 南京传奇生物科技有限公司 基于单结构域抗体的嵌合抗原受体及其使用方法
CN109790222A (zh) * 2016-07-08 2019-05-21 科济生物医药（上海）有限公司 抗密蛋白18a2的抗体及其应用
US20210230272A1 (en) * 2018-06-17 2021-07-29 L&L Biopharma Co., Ltd. Antibody targeting cldn18.2, bispecific antibody, adc, and car, and applications thereof
CN110606891A (zh) * 2018-06-17 2019-12-24 上海健信生物医药科技有限公司 一种针对人cldn18.2的新型抗体分子, 抗原结合片段及其医药用途
US20210214433A1 (en) * 2018-07-25 2021-07-15 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
CN110857322A (zh) * 2018-08-22 2020-03-03 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
CN110862454A (zh) * 2018-08-27 2020-03-06 南京圣和药业股份有限公司 一种抗Claudin18_2抗体及其应用
CN111434692A (zh) * 2019-01-15 2020-07-21 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN116333141A (zh) * 2019-01-15 2023-06-27 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
US10421817B1 (en) * 2019-01-17 2019-09-24 Beijing Mabworks Biotech Co., Ltd. Antibodies binding human Claudin 18.2 and uses thereof
CN109762067A (zh) * 2019-01-17 2019-05-17 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN111235113A (zh) * 2020-01-21 2020-06-05 南京北恒生物科技有限公司 包含嵌合抗原受体的免疫细胞及其用途

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GENBANK: "CAO79130.1: immunoglobulin heavy chain variable region, partial [Vicugna pacos]", 《GENBANK》 *
GENBANK: "CAQ53177.1: surface immunoglobulin M heavy chain variable region, partial [Vicugna pacos]", 《GENBANK》 *
GUOYUN ZHU等: "Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer", 《SCIENTIFIC REPORTS》, vol. 09, no. 01, pages 1 - 11 *
HUA JIANG等: "Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer", 《JOURNAL OF THE NATIONAL CANCER INSTITUTE》, vol. 111, no. 04, pages 409 - 418, XP055642983, DOI: 10.1093/jnci/djy134 *
S.E. AL-BATRAN等: "LBA-06 IMAB362: a novel immunotherapeutic antibody targeting the tight-junction protein component CLAUDIN18.2 in gastric cancer", 《ANNALS OF ONCOLOGY》, vol. 27, no. 02, pages 1 *
徐良额等: "CLDN18.2蛋白在恶性肿瘤治疗中的研究进展", 《中国肿瘤临床》, vol. 46, no. 06, pages 540 - 544 *
曹云新、张松、杨安钢: "Claudin 18在胰腺癌细胞中的表达", 《细胞与分子免疫学杂志》, vol. 25, no. 12, pages 1202 - 1203 *
邵荣光: "基于单克隆抗体的肿瘤免疫治疗", 《药学学报》, vol. 55, no. 06, pages 1110 - 1118 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117551199A (zh) * 2023-11-16 2024-02-13 杭州荣谷生物科技有限公司 一种Claudin18.2纳米抗体的制备方法及其应用
CN117551199B (zh) * 2023-11-16 2024-04-19 杭州荣谷生物科技有限公司 一种Claudin18.2纳米抗体的制备方法及其应用

Also Published As

Publication number Publication date
WO2022011531A1 (zh) 2022-01-20
CN114222761B (zh) 2024-02-20

Similar Documents

Publication Publication Date Title
WO2020143836A1 (zh) Cd73抗体及其制备方法和应用
KR102629905B1 (ko) 항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조
AU2019422629A1 (en) HEAVY-CHAIN ANTIBODIES (VHHs) AGAINST CLAUDIN 18A2 AND USE THEREOF
CA3064534C (en) Anti-human interleukin-2 antibodies and uses thereof
CN113348180A (zh) Ox40抗体及其制备方法和应用
EP4215549A1 (en) Anti-4-1bb-anti-pd-l1 bispecific antibody, and pharmaceutical composition and use thereof
CN113943370A (zh) 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法
CN114222761B (zh) 一种抗cld18a2的单域抗体
CN113527487A (zh) 抗人b7-h3的单克隆抗体及其应用
WO2022224997A1 (ja) 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体
KR20200002451A (ko) 인간 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도
US20240100180A1 (en) Tumor-specific claudin 18.2 antibody-drug conjugates
US20220033501A1 (en) Anti-human tim-3 monoclonal antibody and application thereof
CN117042809A (zh) 抗her2抗体-免疫激动剂缀合物及其应用
US20230212294A1 (en) Anti-b7-h3 antibody and preparation therefor and use thereof
US20220354960A1 (en) Immune checkpoint blocking bispecific molecules
CN110799211A (zh) 特异性识别丛蛋白-信号素-整合素结构域的抗ron单克隆抗体的药物呈递作用及其在肿瘤治疗中的应用
US20220177573A1 (en) Two chimeric antigen receptors specifically binding cd19 and igkappa
US20230348630A1 (en) Antibodies binding bcma and cd3 and uses thereof
WO2024094159A1 (zh) 靶向人源ror1的单域抗体
KR20230078701A (ko) 인간 클라우딘 18.2를 표적화하는 항체 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant